Avantax Advisory Services Inc. Has $396,000 Holdings in Kenvue Inc. (NYSE:KVUE)

Avantax Advisory Services Inc. decreased its position in shares of Kenvue Inc. (NYSE:KVUE) by 14.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 18,372 shares of the company’s stock after selling 3,188 shares during the period. Avantax Advisory Services Inc.’s holdings in Kenvue were worth $396,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the company. Clearstead Advisors LLC acquired a new position in Kenvue in the third quarter worth $25,000. Planned Solutions Inc. bought a new stake in Kenvue during the 4th quarter worth about $27,000. Pacific Capital Wealth Advisors Inc. acquired a new stake in Kenvue in the 4th quarter valued at about $28,000. EverSource Wealth Advisors LLC bought a new position in shares of Kenvue in the third quarter worth about $28,000. Finally, CVA Family Office LLC acquired a new position in shares of Kenvue during the fourth quarter worth approximately $32,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Trading Down 2.2 %

Shares of NYSE:KVUE opened at $19.44 on Friday. Kenvue Inc. has a 52-week low of $17.82 and a 52-week high of $26.74. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.99. The company has a market capitalization of $37.21 billion and a P/E ratio of 24.92. The company has a 50-day simple moving average of $20.01 and a 200 day simple moving average of $20.20.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Tuesday, May 7th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.25 by $0.03. The firm had revenue of $2.89 billion during the quarter, compared to analysts’ expectations of $3.79 billion. Kenvue had a net margin of 9.63% and a return on equity of 21.06%. The firm’s revenue for the quarter was down 24.9% on a year-over-year basis. Sell-side analysts forecast that Kenvue Inc. will post 1.15 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 22nd. Shareholders of record on Wednesday, May 8th were given a dividend of $0.20 per share. The ex-dividend date of this dividend was Tuesday, May 7th. This represents a $0.80 annualized dividend and a yield of 4.12%. Kenvue’s dividend payout ratio (DPR) is presently 102.56%.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. HSBC boosted their price objective on shares of Kenvue from $20.00 to $21.00 and gave the stock a “hold” rating in a research report on Wednesday, May 8th. William Blair initiated coverage on shares of Kenvue in a report on Wednesday, April 3rd. They issued a “market perform” rating for the company. The Goldman Sachs Group began coverage on shares of Kenvue in a report on Friday, March 1st. They issued a “neutral” rating and a $20.00 price target for the company. Sanford C. Bernstein initiated coverage on Kenvue in a report on Thursday, April 11th. They set an “underperform” rating and a $18.00 price objective for the company. Finally, JPMorgan Chase & Co. cut their target price on Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday, February 9th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, Kenvue presently has a consensus rating of “Hold” and an average price target of $24.38.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.